Reduction seen in risk for readmission, wound dehiscence, and hematoma, but no significant differences seen in rates of infection, bleeding ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

毫无疑问，这是GLP-1的时代。近期，在不到一个月的时间内，三笔GLP-1交易相继达成，涉及金额超44亿美元。先是默沙东引进翰森制药的小分子GLP-1RA HS-10535，紧接着箕星药业从闻泰医药引进口服小分子GLP-1RA ...

随着循证证据的累积，胰高血糖素样肽-1受体激动剂（GLP-1 RA）越来越多地被用于青少年肥胖症的治疗。然而，目前尚未明确GLP-1 ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

1 月 10 日，先为达生物宣布，与 Verdiva Bio 就 每周一次口服 GLP-1受体激动剂伊诺格鲁肽等 3 款产品组合达成了在除大中华区及韩国以外的全球开发和商业化许可与合作协议， 总金额高达 24.7 亿美元。